Coronavirus company news summary – TrioMed Active mask confirmed to deactivate Covid-19 virus – 3M and MIT test rapid Covid-19 detection test

15 July 2020 (Last Updated July 15th, 2020 09:36)

Doctor Evidence has announced that its new tools for automated network meta-analysis will be used to find the most effective Covid-19 treatments. The DOC Analytics platform can be used to aggregate the continuously emerging clinical trial data in real time. According to the World Health Organization's International Clinical Trials Registry Platform, there are around 1,798 Covid-19 treatment trials ongoing around the world, as of 12 July.

A team of University of Toronto scientists have tested and confirmed that the Covid-19-causing SARS-CoV-2 virus cannot be recovered after it is applied to i3 BioMedical's TrioMed Active mask. The external surface of the mask reportedly deactivates over 99% of the coronavirus suspension within minutes.

Genalyte has announced the availability of the SARS-CoV-2 Multi-Antigen Serology Panel. The serology test can identify the antibody types present in the blood of the patient following which it can be determined if it is an active or past infection. Based on the type of antibodies present, the test may indicate the presence of an active or past infection. The antibody testing is available at the Toyota Center in Houston.

3M has partnered with Massachusetts Institute of Technology (MIT) researchers to test a new rapid Covid-19 detection test. The teams are currently carrying out accelerated research to explore if a simple-to-use, diagnostic device can offer results with high accuracy in minutes. The team will also test if the device can be mass manufactured.